ArticleAmerican journal of translational research2021
Ginkgo biloba extract improves cognitive function and increases neurogenesis by reducing Aβ pathology in 5×FAD mice.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Ginkgo biloba as a Promising Candidate for Traumatic Brain Injury: Insights From Preclinical and Clinical Studies.Chemistry & biodiversity · 2026Pooled it
- Targeting cellular senescence with Traditional Chinese Medicine: advances in neurodegenerative disorder treatment.Frontiers in neurology · 2026Pooled it
- Water extract ofMolecular medicine reports · 2025Article
- Exploration of natural products for the development of promising cholinesterase inhibitors in Alzheimer's disease treatment.Heliyon · 2025Article
- Natural drug delivery systems for the treatment of neurodegenerative diseases.Molecular biology reports · 2025Review
- Potential therapeutic effects of Ebixa,Frontiers in neuroscience · 2025Article
- Harvesting Health: Phytochemicals in Cognitive Impairment Therapy.Central nervous system agents in medicinal chemistry · 2025Review
- 7-α-O-Methylmorroniside ameliorated brain injury in 5×FAD mice by regulating the gut microbiome and NMDAR2B.Frontiers in pharmacology · 2025Article
- Whole Plant Extracts for Neurocognitive Disorders: A Narrative Review of Neuropsychological and Preclinical Studies.Nutrients · 2024Review
- Metabolomics study to reveal cognitive improvement with treatment of Scrophularia buergeriana.Scientific reports · 2024Article
- New Value ofNutrients · 2024Article
- Pleiotropic attenuating effect ofChinese herbal medicines · 2024Article
- Article
- Article
- Review
- Migratory Response of Cells in Neurogenic Niches to Neuronal Death: The Onset of Harmonic Repair?International journal of molecular sciences · 2023Review
- Qi-fu-yin attenuated cognitive disorders in 5xFAD mice of Alzheimer's disease animal model by regulating immunity.Frontiers in neurology · 2023Article
- Uncovering the pharmacology of Ginkgo biloba folium in the cell-type-specific targets of Parkinson's disease.Frontiers in pharmacology · 2022Article
- Synergistic Neuroprotective Effects of a Natural Product Mixture against AD Hallmarks and Cognitive Decline inNutrients · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies have indicated that the generation of newborn hippocampal neurons is impaired in the early phase of Alzheimer's disease (AD). A potential therapeutic strategy being pursued for the treatment of AD is increasing the number of newborn neurons in the adult hippocampus. Recent studies have demonstrated that ginkgo biloba extract (EGb 761) plays a neuroprotective role by preventing memory loss in many neurodegenerative diseases. However, the extent of EGb 761's protective role in the AD process is unclear. In this study, different doses of EGb 761 (0, 10, 20, and 30 mg/kg; intraperitoneal injections once every day for four months) were tested on 5×FAD mice. After consecutive 4-month injections, mice were tested in learning memory tasks, Aβ, and neurogenesis in the dentate gyrus (DG) of hippocampus and morphological characteristics of neurons in DG of hippocampus. Results indicated that EGb 761 (20 and 30 mg/kg) ameliorated memory deficits. Further analysis indicated that EGb 761 can reduce the number of Aβ positive signals in 5×FAD mice, increase the number of newborn neurons, and increase dendritic branching and density of dendritic spines in 5×FAD mice compared to nontreated 5×FAD mice. It was concluded that EGb 761 plays a protective role in the memory deficit of 5×FAD mice.
Indexed as
Identifiers
33841671PMC8014356W3152789570What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.